Coinfección TB/VIH: Guía Clínica. Versión actualizada – 2010

Holmes, CB, Wood, R, Badri, M, et al. CD4 decline and incidence
of opportunistic infections in Cape Town, South Africa: implications
for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006;
42:464.
Implementing the Stop TB Strategy. A Handbook for National Tuberculosis
Control Programmes. World Health Organization. Geneva. 2008
Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A
Systematic Review. Sujit Suchindran, Emily S. Brouwer , and Annelies
Van Rie. En línea en la dirección http://www.ncbi.nlm.nih.gov/
pmc/articles/PMC2680616/
Improving the diagnosis and treatment of smear-negative pulmonary
and extrapulmonary tuberculosis among adults and adolescents: Recommendations
for HIV-prevalent and resource-constrained settings.
Ginebra, Organización Mundial de la Salud, 2007 (WHO/HTM/
TB/2007.379; WHO/HIV/2007.01).
Jenny-Avital ER, Joseph K. Rifamycin-resistant Mycobacterium tuberculosis
in the highly active antiretroviral therapy era: a report of 3
relapses with acquired rifampin resistance following alternate-day rifabutin
and boosted protease inhibitor therapy. Clin Infect Dis. 2009;
48: 1471-4.
J.M. Cohen; E. Whittaker; S. Walters; H. Lyall; G. Tudor-Williams;
B. Kampmann. Presentation, Diagnosis and Management
of Tuberculosis in HIV-infected Children in the UK. HIV Medicine.
2008;9(5):277–284.
Katherine M. Coyne et al. Pharmacology of second-line antituberculosis
drugs and potential for interactions with antiretroviral agents. AIDS
2009, 23:437–446.
Bibliografía 153